The global Lumbosacral Radicular Pain Management Market is expected to garner a market value of US$ 0.9 Billion in 2023 and is expected to accumulate a market value of US$ 1.4 Billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for Lumbosacral Radicular Pain Management registered a CAGR of 3.2% in the historical period 2018 to 2022.
Lumbosacral radicular pain is a type of pain that originates from the lower back and radiates down the leg, typically caused by compression or irritation of the spinal nerves. The management of lumbosacral radicular pain typically involves a combination of pharmacological and non-pharmacological interventions.
The market for lumbosacral radicular pain management includes a range of products and services, including pain medications, physical therapy, spinal injections, and surgical interventions. The market is driven by factors such as the increasing prevalence of back pain, the aging population, and advancements in medical technology.
Pharmacological interventions for lumbosacral radicular pain management include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and muscle relaxants. Non-pharmacological interventions include physical therapy, chiropractic care, and acupuncture. Spinal injections, such as epidural steroid injections, can also be used to manage lumbosacral radicular pain. In cases where these interventions are ineffective, surgical interventions such as discectomy or laminectomy may be considered.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 0.9 Billion |
| Anticipated Forecast Value (2033) | US$ 1.4 Billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Lumbosacral Radicular Pain Management reflected a value of 3.2% during the historical period, 2018 to 2022. The growth of the market is primarily driven by the increasing prevalence of back pain, particularly in the aging population.
In addition, technological advancements in medical devices and minimally invasive surgical procedures are expected to further drive the growth of the market. For instance, the development of implantable neurostimulation devices and minimally invasive surgical techniques for spinal decompression and fusion are expected to increase the demand for these procedures.
Furthermore, the growing awareness and acceptance of non-pharmacological interventions, such as physical therapy, chiropractic care, and acupuncture, are expected to boost the growth of the market. These interventions are becoming increasingly popular as they offer non-invasive and cost-effective alternatives to traditional pharmacological treatments.
Overall, the market for Lumbosacral Radicular Pain Management is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Increasing Prevalence of Back Pain to push market growth
The increasing prevalence of back pain is one of the key drivers that is expected to push the growth of the lumbosacral radicular pain management market in the coming years. Back pain is a common health problem that affects millions of people worldwide, and lumbosacral radicular pain is a type of back pain that is caused by compression or irritation of the spinal nerves.
According to the World Health Organization (WHO), low back pain is one of the leading causes of disability worldwide, affecting over 540 million people globally. Back pain is also a major cause of absenteeism from work and can have a significant impact on an individual's quality of life.
The increasing prevalence of back pain is primarily driven by factors such as sedentary lifestyles, poor posture, and obesity. As people spend more time sitting at desks or in front of screens, they are more susceptible to developing back pain.
The aging population is also contributing to the growing prevalence of back pain. As people age, the discs in the spine degenerate and become more susceptible to injury, which can lead to back pain.
As the prevalence of back pain continues to increase, the demand for effective treatments for lumbosacral radicular pain management is expected to rise. This is expected to drive the growth of the market for lumbosacral radicular pain management in the coming years, as healthcare providers and patients seek out effective and innovative treatments for this condition.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
Despite the growing awareness of the importance of maintaining good oral health, many people still lack awareness of gum disease and its treatment options. This can limit demand for Lumbosacral Radicular Pain Management products and services.
Additionally, the cost of Lumbosacral Radicular Pain Management can be a barrier for many people, particularly those without insurance coverage. This can limit demand for treatment options and make it more challenging for companies to generate revenue.
Companies operating in the Lumbosacral Radicular Pain Management market must comply with regulatory requirements related to product safety and efficacy. This can be challenging and costly, particularly for smaller companies without significant resources. Overall, companies operating in the Lumbosacral Radicular Pain Management market must navigate these challenges to capture market share and drive growth. By developing innovative products, building strong brands, and effectively communicating the benefits of their offerings, companies can overcome these challenges and succeed in this market.
Increasing awareness and diagnosis of the condition Shaping Landscape for Lumbosacral Radicular Pain Management in South & East Asia
The lumbosacral radicular pain management market in South and East Asia is expected to experience significant growth in the coming years. The region has a large population and a growing aging population, which is expected to increase the prevalence of lumbosacral radicular pain and drive demand for effective treatments.
In addition, increasing healthcare spending and improving healthcare infrastructure in countries such as India, China, and Japan are contributing to the growth of the market. These countries are investing heavily in the development of their healthcare systems, including the expansion of hospital networks, the adoption of new technologies, and the training of healthcare professionals.
The market in South and East Asia is expected to continue to grow, driven by increasing demand for effective treatments for lumbosacral radicular pain management. Additionally, the increasing adoption of non-pharmacological interventions such as physical therapy, chiropractic care, and acupuncture in the region is expected to contribute to the growth of the market. Overall, the lumbosacral radicular pain management market in South and East Asia is turning out to be a promising and growing market with significant potential for further expansion.
Increasing Focus on Technological advancements Shaping Landscape for Lumbosacral Radicular Pain Management in North America
North America is one of the largest markets for lumbosacral radicular pain management globally, and several factors are boosting the growth of this market. Firstly, the region has a large aging population that is more prone to develop lumbosacral radicular pain due to degeneration of spinal discs. This demographic trend has been a major driver of the market growth in the region, as it has increased the demand for effective treatments and therapies.
Secondly, there is a high prevalence of back pain in North America, which has also contributed to the growth of the lumbosacral radicular pain management market. Back pain is a common health problem that affects millions of people in the region, and lumbosacral radicular pain is one of the most common causes of this type of pain.
Thirdly, the region has a highly developed healthcare system with advanced medical technologies, which has enabled the development and adoption of innovative treatments for lumbosacral radicular pain management. This has made the market highly competitive, as companies are constantly developing new treatments and technologies to meet the needs of patients and healthcare providers.
Finally, increasing healthcare expenditure and rising patient awareness about the available treatment options are also driving the growth of the market. Patients are increasingly seeking out effective and minimally invasive treatments for lumbosacral radicular pain, and healthcare providers are responding by offering a range of treatment options to meet their needs.
In conclusion, the high prevalence of back pain, a large aging population, advanced healthcare infrastructure, and increasing patient awareness are the main factors boosting the market for lumbosacral radicular pain management in North America. With continued innovation and investment in the development of new treatments and technologies, the market is expected to grow further in the coming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oral route of administration to hold a significant share and push market growth
The route of administration segment that is likely to account for a significant share of the lumbosacral radicular pain management market is the oral segment. Oral medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and opioids, are commonly used to manage lumbosacral radicular pain.
These medications are widely available, easy to administer, and can provide effective pain relief for many patients. Additionally, the oral route of administration allows for precise dosing and titration of medication to manage pain levels effectively.
Furthermore, the oral route of administration is relatively inexpensive compared to other routes, such as implantable devices or intravenous injections, making it more accessible to a broader range of patients.
Overall, the oral segment is likely to remain a significant contributor to the lumbosacral radicular pain management market due to its convenience, effectiveness, and accessibility.
Hospital pharmacies segment to hold a significant share and push market growth
The end-user segment that is likely to account for a significant share of the lumbosacral radicular pain management market is the hospital pharmacies segment. Hospital pharmacies are the primary healthcare providers for patients with lumbosacral radicular pain, and they have the necessary resources and equipment to provide comprehensive pain management services.
Additionally, hospitals have access to a wide range of pain management treatments, including medications, injections, and physical therapy, which can be tailored to meet the needs of individual patients. They also have a multidisciplinary team of healthcare professionals, including pain management specialists, neurologists, and physical therapists, who work together to provide coordinated care for patients.
Moreover, hospital pharmacies have a large patient base, which enables them to leverage economies of scale to negotiate better prices with suppliers and manufacturers. This can help to reduce the overall cost of treatment for patients and healthcare providers.
Overall, the hospital pharmacies segment is likely to remain a significant contributor to the lumbosacral radicular pain management market due to its resources, expertise, and ability to provide comprehensive care to patients.
Key players in the market include companies such as Competition Deep Dive, Semnur Pharmaceuticals, Inc., Eliem Therapeutics, Forest Laboratories, Medtronic Spinal and Biologics, Teva Pharmaceutical, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Eli Lilly & Company, along with healthcare providers and technology companies among other global players.
The promising results of this study offer a new avenue for treating chronic back pain and improving the quality of life for those who suffer from it. The study was conducted by several universities across Australia and Europe and is a significant breakthrough in the field of pain management. In conclusion, the development of a new therapy for chronic back pain that focuses on retraining the communication between the back and the brain offers hope for millions of people worldwide. The randomized controlled trial conducted by researchers at the University of New South Wales (UNSW) Sydney and Neuroscience Research Australia (NeuRA) demonstrated the effectiveness of this treatment in improving chronic back pain.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 0.9 Billion |
| Market Value in 2033 | US$ 1.4 Billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Competition Deep Dive, Semnur Pharmaceuticals, Inc., Eliem Therapeutics, Forest Laboratories, Medtronic Spinal and Biologics, Teva Pharmaceutical, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Eli Lilly & Company |
| Customization | Available Upon Request |
The United States, India, and Germany dominate the global market.
The market is forecast to register a CAGR of 5% through 2033.
From 2018 to 2022, the market registered a CAGR of 3.2%.
Technological advancement is the current market trends.
The global market size is to reach US$ 1.4 billion by 2033.
1. Executive Summary | Lumbosacral Radicular Pain Management Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Cyclobenzaprine 5.3.2. Oxycodone 5.3.3. Tramadol 5.3.4. Gabapentin 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Topical 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospital Pharmacy 7.3.2. Retail Pharmacy 7.3.3. Online Pharmacy 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By End User 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By End User 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By End User 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By End User 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By End User 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By End User 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By End User 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By End User 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By End User 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By End User 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By End User 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By End User 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By End User 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By End User 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By End User 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By End User 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Scilex Pharmaceuticals, Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Semnur Pharmaceuticals, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Eliem Therapeutics 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Forest Laboratories 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Medtronic Spinal and Biologics 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Teva Pharmaceutical 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. 3M Company 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Ultradent Products Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Nobel Biocare Holdings AG 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Eli Lilly & Company 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Lumbosacral Radicular Pain Management Market
